Turnstone Biologics Corp. (TSBX)
Aug 11, 2025 - TSBX was delisted (reason: acquired by XOMA)
0.3550
0.00 (0.00%)
Inactive · Last trade price on Aug 8, 2025
Turnstone Biologics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 16.69 | 28.93 | 17.8 | 34.73 | 123.38 |
Short-Term Investments | - | - | 76.98 | 47.33 | 37.64 |
Cash & Short-Term Investments | 16.69 | 28.93 | 94.78 | 82.06 | 161.02 |
Cash Growth | -73.26% | -69.48% | 15.50% | -49.04% | - |
Receivables | - | - | 0.19 | 8.73 | 6.72 |
Prepaid Expenses | 0.37 | 3.19 | 4.66 | 5.08 | 9.23 |
Restricted Cash | 1.91 | 0.12 | 0.12 | 0.38 | 0.38 |
Other Current Assets | 2.15 | 1.99 | 2.81 | 1.75 | - |
Total Current Assets | 21.11 | 34.22 | 102.55 | 98 | 177.34 |
Property, Plant & Equipment | - | 5.11 | 9.12 | 14.36 | 9.37 |
Other Long-Term Assets | - | 0.81 | 1.14 | 2.58 | 0.54 |
Total Assets | 21.11 | 40.14 | 112.82 | 114.94 | 187.24 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.69 | 0.87 | 0.04 | 3.44 | 0.03 |
Accrued Expenses | 3.25 | 6.24 | 9.91 | 10.22 | 14.03 |
Current Portion of Leases | 0.41 | 1.09 | 2.03 | 1.96 | 0.66 |
Current Income Taxes Payable | - | - | - | - | 0.25 |
Current Unearned Revenue | - | - | - | 15.14 | 33.03 |
Other Current Liabilities | - | - | - | 4.06 | 6.97 |
Total Current Liabilities | 6.35 | 8.2 | 11.97 | 34.83 | 54.98 |
Long-Term Leases | - | 0.1 | 1.19 | 3.21 | 2.02 |
Long-Term Unearned Revenue | - | - | - | 4.16 | 39.37 |
Other Long-Term Liabilities | - | 0.37 | 0.99 | 2.27 | 0.97 |
Total Liabilities | 6.35 | 8.67 | 14.15 | 44.46 | 97.34 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0 | 0.02 |
Additional Paid-In Capital | 279.83 | 279.24 | 275.52 | 20.5 | 9.1 |
Retained Earnings | -264.89 | -247.6 | -176.76 | -121.56 | -90.72 |
Comprehensive Income & Other | -0.2 | -0.2 | -0.12 | -0.41 | -0.25 |
Total Common Equity | 14.76 | 31.47 | 98.67 | -101.47 | -81.85 |
Shareholders' Equity | 14.76 | 31.47 | 98.67 | 70.48 | 89.9 |
Total Liabilities & Equity | 21.11 | 40.14 | 112.82 | 114.94 | 187.24 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.41 | 1.19 | 3.21 | 5.17 | 2.68 |
Net Cash (Debt) | 16.28 | 27.74 | 91.56 | 76.9 | 158.34 |
Net Cash Growth | -72.96% | -69.71% | 19.07% | -51.44% | - |
Net Cash Per Share | 0.70 | 1.20 | 7.92 | 30.95 | 58.65 |
Filing Date Shares Outstanding | 23.14 | 23.14 | 23.1 | 3.03 | 2.15 |
Total Common Shares Outstanding | 23.14 | 23.14 | 23.1 | 2.92 | 2.15 |
Working Capital | 14.76 | 26.02 | 90.58 | 63.17 | 122.37 |
Book Value Per Share | 0.64 | 1.36 | 4.27 | -34.80 | -38.08 |
Tangible Book Value | 14.76 | 31.47 | 98.67 | -101.47 | -81.85 |
Tangible Book Value Per Share | 0.64 | 1.36 | 4.27 | -34.80 | -38.08 |
Machinery | - | 10.74 | 11.73 | 14.04 | 5.93 |
Construction In Progress | - | - | - | - | 2.94 |
Leasehold Improvements | - | 1.31 | 1.31 | 1.31 | 1.31 |